A massive transfusion protocol is designed to rapidly replace blood loss with a balanced mix of blood components to maintain both oxygen delivery and coagulation. Transfusing only red blood cells can dilute clotting factors and platelets, leading to ongoing bleeding. Providing red cells along with plasma (for clotting factors) and platelets (for primary hemostasis) in a 1:1:1 ratio helps preserve coagulation and more closely approximates whole blood, which can improve bleeding control and outcomes when massive hemorrhage occurs. This approach emphasizes getting all components to the patient quickly rather than delaying plasma or platelets to save resources, and it avoids hypothermia, since warming blood products and maintaining normothermia are important to prevent coagulopathy.

In a massive transfusion, the goal is to replace blood components in a way that preserves coagulation while restoring oxygen delivery. Red blood cells address oxygen transport, but transfusing many RBCs without other components dilutes clotting factors and platelets, risking coagulopathy. Plasma provides the coagulation factors needed for proper clot formation, and platelets support primary hemostasis. Using a balanced 1:1:1 ratio of plasma, platelets, and red cells helps recreate a whole-blood-like mix, supporting both clotting and oxygen delivery and is associated with better outcomes in severe hemorrhage. Delaying plasma after giving RBCs, or using only RBCs, or transfusing whole blood without regard to a balanced component mix, do not maintain that critical balance.

An antibody screen looks for unexpected antibodies in a patient’s plasma that could attack donor red cells. It uses screening cells that carry a broad set of common red cell antigens. If the screen is negative, the risk of a reaction is low and a crossmatch can confirm compatibility with a chosen donor unit. If the screen is positive, the specific antibody (or antibodies) is identified, revealing exactly which red cell antigen the patient’s plasma targets. Once the antibody is known, you select donor units that lack the corresponding antigen (antigen-negative for that antibody) to prevent a transfusion reaction. This process helps ensure safer transfusions and may lead to broader or extended antigen matching for future transfusions.

RhCE antigens C/c and E/e are encoded by the same gene and tend to be inherited together on common haplotypes. Because of this genetic linkage, when a person is immunized against one of these antigens, they are often exposed to the other as well. As a result, anti-E frequently appears alongside anti-c in the same individual. This paired pattern matters in transfusion testing because detecting anti-E should prompt evaluation for anti-c too, since both can cause transfusion reactions if donor cells carry the corresponding antigens. The other pairings don’t show this consistent co-occurrence as a rule, so anti-E and anti-c is the most expected combined antibody pattern.